Studies have suggested that Oct4 and Nanog may participate in the tumorigenicity and tumor progression of various types of cancer, including breast cancer, glioma, human endometrial adenocarcinoma, gastric cancer and colorectal cancer (29–33). Here, NANOG is linked to endometrium adenocarcinoma.